Cargando…

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia

Cardiovascular disease (CVD) is the leading cause of death worldwide and is the clinical manifestation of the atherosclerosis. Elevated LDL-cholesterol levels are the first line of therapy but the increasing prevalence in type 2 diabetes mellitus (T2DM) has positioned the cardiometabolic risk as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguilar-Ballester, María, Hurtado-Genovés, Gema, Taberner-Cortés, Alida, Herrero-Cervera, Andrea, Martínez-Hervás, Sergio, González-Navarro, Herminia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826980/ https://www.ncbi.nlm.nih.gov/pubmed/33440821 http://dx.doi.org/10.3390/ijms22020660

Ejemplares similares

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
por: Jiménez-Martí, Elena, et al.
Publicado: (2022)

Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14)
por: Herrero-Cervera, Andrea, et al.
Publicado: (2021)

Impact of Cholesterol Metabolism in Immune Cell Function and Atherosclerosis
por: Aguilar-Ballester, María, et al.
Publicado: (2020)

Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes
por: Martínez-Hervás, Sergio, et al.
Publicado: (2019)

Understanding the Impact of Dietary Cholesterol on Chronic Metabolic Diseases through Studies in Rodent Models
por: Vinué, Ángela, et al.
Publicado: (2018)

Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia
por: Lim, Phillip, et al.
Publicado: (2022)

Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease
por: Vesa, Cosmin Mihai, et al.
Publicado: (2023)

Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System
por: Toffoli, Barbara, et al.
Publicado: (2016)

Diabetes Dyslipidemia
por: Schofield, Jonathan D., et al.
Publicado: (2016)

Treatment of dyslipidemia in patients with type 2 diabetes
por: Vijayaraghavan, Krishnaswami
Publicado: (2010)

Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
por: Sunil, Bhuvana, et al.
Publicado: (2020)

Dyslipidemia and cardiovascular disease risk factors in patients with type 1 diabetes: A single-center experience
por: Krepel Volsky, Sari, et al.
Publicado: (2021)

Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study
por: Kaze, Arnaud D., et al.
Publicado: (2021)

Identification of susceptibility loci for cardiovascular disease in adults with hypertension, diabetes, and dyslipidemia
por: Song, Youhyun, et al.
Publicado: (2021)

Pathophysiology of Diabetic Dyslipidemia
por: Hirano, Tsutomu
Publicado: (2018)

Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children
por: D'Adamo, Ebe, et al.
Publicado: (2015)

Correction to: Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study
Publicado: (2021)

The Problem of Abnormal Body Weight and Dyslipidemia as Risk Factors for Cardiovascular Diseases in Children and Adolescents with Type 1 Diabetes
por: Noras, Katarzyna, et al.
Publicado: (2021)

Unsaturated Oral Fat Load Test Improves Glycemia, Insulinemia and Oxidative Stress Status in Nondiabetic Subjects with Abdominal Obesity
por: Martinez-Hervas, Sergio, et al.
Publicado: (2016)

Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes
por: Pokharel, Daya Ram, et al.
Publicado: (2017)

Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
por: Musunuru, Kiran
Publicado: (2010)

Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
por: Vekic, Jelena, et al.
Publicado: (2023)

Management of diabetic dyslipidemia: An update
por: Jialal, Ishwarlal, et al.
Publicado: (2019)

Role of the Gut in Diabetic Dyslipidemia
por: Stahel, Priska, et al.
Publicado: (2020)

Updates on dyslipidemia in patients with diabetes
por: Ide, Shintaro, et al.
Publicado: (2023)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
por: Rana, Khyatiben, et al.
Publicado: (2019)

Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia
por: Zaman Huri, Hasniza, et al.
Publicado: (2013)

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

HM-Chromanone Ameliorates Hyperglycemia and Dyslipidemia in Type 2 Diabetic Mice
por: Park, Jae Eun, et al.
Publicado: (2022)

Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment
por: Higgins, Victoria, et al.
Publicado: (2017)

The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus
por: Chatziralli, Irini P.
Publicado: (2017)

Assessment of Dyslipidemia, Lipid Ratios, and Atherogenic Indices as Cardiovascular Risk Factors in Prediabetic and Diabetic Subjects
por: Rathi, Himani, et al.
Publicado: (2022)

Contribution of Known Genetic Risk Variants to Dyslipidemias and Type 2 Diabetes in Mexico: A Population-Based Nationwide Study
por: Huerta-Chagoya, Alicia, et al.
Publicado: (2020)

Diabetes and dyslipidemia: characterizing lipoprotein metabolism
por: Tomkin, GH, et al.
Publicado: (2017)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
por: Ray, Kausik K., et al.
Publicado: (2019)

Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESA-Opinion Study
por: Pallarés-Carratalá, Vicente, et al.
Publicado: (2023)

Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts
por: Qi, Qibin, et al.
Publicado: (2012)

Obstructive Sleep Apnea and Cardiovascular Risk: The Role of Dyslipidemia, Inflammation, and Obesity
por: Zdravkovic, Marija, et al.
Publicado: (2022)

Predictors of Dyslipidemia Over Time in Youth With Type 1 Diabetes: For the SEARCH for Diabetes in Youth Study
por: Shah, Amy S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7c7kncdbv68bp1mlls0qpeh52n